ABSTRACT
OBJETIVO: Relatar tratamento de retinopatia por radiação em paciente submetido à radioterapia por linfoma em órbita direita com injeção intravítrea de bevacizumab (Avastin®). Paciente de 55 anos, diabético, com diagnóstico de linfoma MALT orbitário há três anos, tratado com radioterapia local (dose: 35Gy) há dois anos, com queixa de redução da acuidade visual do olho direito há quatro meses. Ao exame oftalmológico, apresentava alterações sugestivas de retinopatia por radiação, bem como espessura macular à tomografia de coerência óptica de 480 µm. Paciente foi submetido à injeção intravítrea (0,05 ml) de bevacizumab (Avastin®) no olho direito, apresentando redução do edema macular, bem como melhora discreta da acuidade visual. Neste caso, o tratamento da retinopatia por radiação com injeção intravítrea de bevacizumab (Avastin®) foi relativamente útil, com melhora discreta da acuidade visual, devido à regressão do edema macular.
PURPOSE: To report a case of radiation retinopathy treatment with intravitreal injection of bevacizumab (Avastin®) in a patient undergoing radiotherapy for lymphoma in the right orbit. Patient of 55 years-old male, diabetic, diagnosed with an orbital MALT lymphoma three years ago, treated with local radiotherapy (dose: 35Gy) two years ago, complaining of reduced visual acuity of the right eye for about four months. During the ophthalmologic evaluation, he had an exam suggestive of radiation retinopathy. Macular thickness at the optical coherence tomography was 480 µm. Patient was referred to intravitreal injection (0.05 ml) of bevacizumab (Avastin®) in the right eye, showing reduction of macular edema and mild improvement of visual acuity. In this case, the treatment of radiation retinopathy with intravitreal injection of bevacizumab (Avastin®) was relatively useful, with mild improvement of visual acuity due to the regression of macular edema.
Subject(s)
Humans , Male , Middle Aged , Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal/therapeutic use , Macular Edema/drug therapy , Radiation Injuries/drug therapy , Intravitreal Injections , Lymphoma, B-Cell/radiotherapy , Treatment Outcome , Visual AcuityABSTRACT
Many Koreans, in addition to Japanese, were killed or injured by the atomic bombs detonated over Hiroshima and Nagasaki, Japan, in 1945. Our study examined noncancer diseases of Korean A-bomb survivors in residence at Hapcheon, Republic of Korea and evaluated whether they had significantly higher prevalence of noncancer diseases than non-exposed people. We evaluated a number of tests, including anthropometric measurements, blood pressure, blood chemistry, hepatitis B surface antigen, and urinalysis, of survivors (n=223) and controls (n=372). Univariate analysis revealed significantly lower fasting glucose and creatinine, and higher diastolic blood pressure, aspartate aminotransferase, alanine aminotransferase, and blood urea nitrogen levels in the survivors than in the controls. The calculation of crude prevalence ratios (PRs) revealed that A-bomb survivors had a significantly higher prevalence of hypertension (PR, 1.16; 95% CI, 1.00-1.35) and chronic liver disease (2.20; 1.59-3.06) than controls. After adjusting for covariates (age, sex, body mass index, marital status, education, alcohol consumption, and smoking), A-bomb survivors had a significantly higher prevalence of hypertension (1.24; 1.06-1.44), chronic liver disease (2.07; 1.51-2.84), and hypercholesterolemia (1.79; 1.11-2.90) than controls. This study suggests that A-bomb exposure is associated with a higher prevalence of non-cancer diseases in Korean survivors.